Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is ...

Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and ...

A week ago, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) came out with a strong set of first-quarter numbers that ...

Viridian Therapeutics (VRDN) priced upsized concurrent public offerings totaling $350M in gross proceeds, including $225M of ...

Phase 3 trial data showed elegrobart significantly improved proptosis and diplopia in patients with moderate to severe chronic thyroid eye disease.

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

Unfortunately, there are plenty of stocks that have been left behind. Some of these underperformers may be providing ...

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.

Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027. Viridian ...